| Literature DB >> 31825163 |
Katie E Chatwin1, Caroline A Abbott1, Andrew J M Boulton2,3, Frank L Bowling2, Neil D Reeves1.
Abstract
The predominant risk factor of diabetic foot ulcers (DFU), peripheral neuropathy, results in loss of protective sensation and is associated with abnormally high plantar pressures. DFU prevention strategies strive to reduce these high plantar pressures. Nevertheless, several constraints should be acknowledged regarding the research supporting the link between plantar pressure and DFUs, which may explain the low prediction ability reported in prospective studies. The majority of studies assess vertical, rather than shear, barefoot plantar pressure in laboratory-based environments, rather than during daily activity. Few studies investigated previous DFU location-specific pressure. Previous studies focus predominantly on walking, although studies monitoring activity suggest that more time is spent on other weight-bearing activities, where a lower "peak" plantar pressure might be applied over a longer duration. Although further research is needed, this may indicate that an expression of cumulative pressure applied over time could be a more relevant parameter than peak pressure. Studies indicated that providing pressure feedback might reduce plantar pressures, with an emerging potential use of smart technology, however, further research is required. Further pressure analyses, across all weight-bearing activities, referring to location-specific pressures are required to improve our understanding of pressures resulting in DFUs and improve effectiveness of interventions.Entities:
Keywords: diabetic ulcer; peripheral neuropathy; plantar pressure; pressure feedback; pressure-time integral
Mesh:
Substances:
Year: 2019 PMID: 31825163 PMCID: PMC7317473 DOI: 10.1002/dmrr.3258
Source DB: PubMed Journal: Diabetes Metab Res Rev ISSN: 1520-7552 Impact factor: 4.876
Figure 1Examples of equipment used to measure plantar pressure. A, AMTI force platform (Advanced Medical Technology, Inc. Watertown, MA). B, BTS P‐walk pressure plate (MA). C, PressureStat (Medical Gait Technology BY, Emmen, The Netherlands). D, F‐scan pressure assessment system insole (Tekscan, Inc., Boston, MA). The equipment A‐C are typically used to collect barefoot pressure data, whereas D is placed in‐shoe
Demographic data for participants classified into selected groups, in reviewed plantar pressure studies
| First Author (Year) | Ulcerated group (DU) | No in‐study ulcer, neuropathic group (DPN) | Diabetes control group (DC) | Healthy controls (HC) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DFU (n=) | DFU History (n=) | % Type 2 | % Male | Age (years) | BMI (kg/m2) | Diabetes duration (years) | DPN (n=) | DFU History (n=) | % Type 2 | % Male | Age (years) | BMI (kg/m2) | Diabetes duration (years) | DC (n=) | % Type 2 | % Male | Age (years) | BMI (kg/m2) | HC (n=) | % Male | Age (years) | BMI (kg/m2) | |
| Abbott (2017) | 9 | 9 | — | 88.8 | 62.6 (11.5) | 31.2 (8.2) | — | 6 | 6 | — | 100 | 56.7 (7.1) | 32.3 (6.2) | — |
| 12 | 33.3 | 58.0 (8.3) | 26.2 (3.8) | ||||
| Armstrong (1998) | 70 | — | — | 74 | 52.3 (10.3) | 30.9 (5.7) | 14.3 (9.2) | 149 | 0 | — | 33 | 51.8 (10.4) | 32.3 (6.2) | 9.2 (8.8) |
|
| |||||||
| Bacarin (2009) | 10 | 10 | 90 | 80 | 58.2 (6.7) | 27 (5.5) | 17.5 (9.3) | 17 | 0 | 94 | 47 | 54.7 (7.8) | 26.1 (4.6) | 13.4 (8.4) |
| 20 | 35 | 48.7 (9.4) | 24.3 (2.6) | ||||
|
| 99 | 99 | 70.7 | 69.7 | 60 (10.5) | 29.4 (5.5) | 17 (9.5) | 152 | 0 | 86.8 | 62.5 | 57 (13.5) | 30.5 (6.8) | 12 (10.8) |
|
| |||||||
|
| 47 | 95.7 | 68 | 30 | 19 | 544 | — | — | 98.3 | 67 | 30.3 | 15 |
|
| |||||||||
|
|
| 76 | — | 100 | — | 66 (7.2) | 31.18 | — | 33 | 100 | — | 62.8 (7.1) | 31.0 | 19 | — | 68.1 (5.2) | 24.3 | ||||||
|
|
| 49 | 49 | — | 77.6 | 62.9 (10.3) | 28.1 | — |
|
| |||||||||||||
|
| 73 | 32 | 76.7 | 67.1 | 59 (11) | 29.6 (7.1) | 16 (12) | 175 | 55 | 81.7 | 42.9 | 58 (13) | 31.3 (7.0) | 13 (10) |
|
| |||||||
|
|
| 15 | — | 100 | 60 | 57 (6) | 28.2 | >5 |
| 16 | 31 | 46 (11) | 25.3 | ||||||||||
|
| 49 | 49 | — | — | 61.7 (12.4) | 30 | — | 14 | 0 | — | — | 66.0 (8.9) | 30.6 | — | 34 | — | — | 66.6 (9.1) | 28.6 |
| |||
| Waaijman (2014) | 71 | 71 | 71.8 | 85.9 | 62.8 (11.2) | 30.6 (6.2) | 16.7 (13.2) | 100 | 100 | 71 | 80 | 63.6 (9.4) | 30.7 (5.3) | 17.7 (13.8) |
|
| |||||||
Note: Reported means and standard deviations (SD) when available. Diabetes duration was omitted from the DC group as it was not provided in any of the studies, as was ulcer history. Diabetes control = no neuropathy and no ulcer.
Within the DPN group, not all participants are thought to have peripheral neuropathy based on reported mean (SD) VPT scores, exact numbers of neuropathy patents were not provided.
Not all participants within this study had peripheral neuropathy, however the majority did: DU ‐ 38/47, DPN ‐ 259/544.
These studies did not mention previous ulcer history, however active ulcers were excluded.
This study included only one group of participants who had remained healed following previous ulceration.
Study states predominantly males but does not give percentage.
Mean (SE) values were reported in this study.
Barefoot and in‐shoe plantar pressure data of selected participant groups, taking into account plantar area of pressure measurement, between studies
| First Author (Year) | Peak Plantar Pressure (kPa) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foot pressure measurement | Whole foot | Forefoot | Midfoot | Rearfoot | Hallux | |||||||||||||||||
| System | Specifications | DU | DPN | DC | HC | DU | DPN | DC | HC | DU | DPN | DC | HC | DU | DPN | DC | HC | DU | DPN | DC | HC | |
|
| ||||||||||||||||||||||
| Abbott (2017) | PressureStat | 449 (178) | 231 (107) | 237 (61.8) | ||||||||||||||||||
| Armstrong (1998) | EMED | 4pixels per cm2 | 831 (247) | 627 (214) | ||||||||||||||||||
|
| Pedar | 50 Hz, 1.6‐2.2cm2 | 367 (86.2) | 368 (89.2) | 348 (88.4) | 291 (152) | 205 (119) | 139 (76.4) | 342 (119) | 342 (76.9) | 337 (95.9) | 270 (137) | 306 (112) | 307 (111) | ||||||||
| Frykberg (1998) | F‐Scan | 5mm2 | 657 (304) | 481 (235) | ||||||||||||||||||
| Lavery (2003) | EMED | 4pixels/cm2 | 955 (264) | 851 (273) | ||||||||||||||||||
|
| EMED | 100 Hz, 4 sensors/cm2 | 501 (198) | 448 (133) | 364 (75) | 150 (52) | 165 (60) | 118 (24) | 425 (118) | 419 (109) | 359 (93) | 463 (243) | 514 (286) | 355 (149) | ||||||||
| Owings (2009) | EMED | 50mm2 | 566 (316) | 486 (242) | ||||||||||||||||||
| Pham (2000) | F‐Scan | 706 (373) | 522 (255) | |||||||||||||||||||
|
| Pedar | 100 Hz | 246 (56.3) | 219 (35.3) | 114 (52.2) | 75.7 (31.1) | 220 (40.4) | 197 (27.8) | ||||||||||||||
|
| EMED | 480 (18) | 405 (28) | 407 (17) | ||||||||||||||||||
| Waaijman (2014) | EMED | 50 Hz, 4 sensors/cm2 | 1042 (260) | 935 (307) | ||||||||||||||||||
|
| ||||||||||||||||||||||
|
| F‐Scan | 219 (16) | 194 (2) | 383 (50) | 303 (5) | 267 (85) | 141 (2) | 241 (27) | 266 (3) | 172 (20) | 200 (4) | |||||||||||
| Owings (2009) | Pedar | 1.85 cm2 | 207 (68) | 214 (71) | ||||||||||||||||||
| Pliance | 0.194 cm2 | 291 (132) | 304 (124) | |||||||||||||||||||
| Waaijman (2014) | Pedar | 50 Hz, 1 cm2 | 261 (83) | 249 (77) | ||||||||||||||||||
Note: Reported mean (SD) peak plantar pressure (kPa) while walking.
Abbreviations: DC, diabetes control group with no DFU history and no peripheral neuropathy; DPN, diabetes patients with peripheral neuropathy who did not ulcerate in‐study; DU, diabetes patients who developed an ulcer in‐study; HC, non‐diabetic, healthy controls.
These studies placed in‐soles in socks to record pressure.
This study split forefoot into medial and lateral, the highest values were reported, lateral for DU and DPN, medial for HC.
This study split forefoot into the five metatarsal heads, the highest value (third MTH) are shown.
Some analysis was conducted using a sensor specification of 50 Hz, 2 sensors/cm2.
Reported pressure at heel strike and push‐off, used value from heel strike for rearfoot and push‐off for forefoot and midfoot as these were the highest.
Mean (SE) values were reported in this study.
This study split the forefoot into multiple sites, the location with the highest value was used: DU – first MTH, DPN – second‐fourth MTH.
Advantages and disadvantages of barefoot and in‐shoe pressure assessment methods
| Assessment type | Advantages | Disadvantages |
|---|---|---|
| Barefoot |
Easy to use Durable Embedded in floor to allow normal gait Allows assessment of “base” plantar pressure development without footwear |
Restricted to laboratories Requires familiarisation to ensure natural gait Can be limited by patient's ability to make contact with the platform Requires multiple trials Walking barefoot presents a risk to diabetic neuropathy patients Does not account for pressure‐reducing nature of footwear |
| In‐shoe |
Portable system Allows multiple footsteps per trial Less risk to the diabetic foot Allows assessment of pressure‐reducing nature of footwear |
Majority of systems involve the participant being tethered by cables Possibility of sensor slipping and becoming damaged |
Characteristics of studies where plantar pressure feedback is provided
| First author (year) | Feedback method | Area where feedback provided | Other areas monitored? | Retention period | Pressure at baseline | Pressure at end of retention | Change to pressure at end of retention | Pressure changes elsewhere | Patient (n =) |
|---|---|---|---|---|---|---|---|---|---|
|
| Graph illustrating plantar pressure target range (40–80% of baseline PPP, for 70% of steps), 1 lab visit | 1 at‐risk area | Y | 10 days | 242 (12)* | 167 (11)* | Reduction | Contralateral lateral midfoot increased significantly. The at‐risk lateral midfoot increased slightly | 21 |
|
| Audio alarm triggered when pressure exceeded 40% of baseline PPP ‐ worn for 2 weeks | Active ulcer site | N | 2 weeks | 450 | 200 | Reduction | n/a | 1 |
| Pataky (2010) | Graph illustrating plantar pressure target range (40–80% of baseline PPP, for 70% of steps), 1 lab visit | 1 at‐risk area | N | 10 days | 262 (70) | 210 (51) | Reduction | n/a | 13 |
|
| FEETME pressure map analysis (target pressure 40–80% of baseline for 70% of steps) ‐ 1 visit | 1 at‐risk area | Y | 6 weeks | — | — | Reduction | No other at‐risk areas developed | 6 |
|
| Visual and verbal feedback on gait and forefoot peak pressure, 2 days of feedback | Forefoot | Y | 1 week | — | — | No changes | no changes | 29 |
|
| Continual visual and auditory feedback on sustained high pressure via smartwatch | Both feet (8 sensor sites covering whole foot) | n/a | Continual feedback provided | No pressure data reported, DFU recurrence rates reduced by 71% in the intervention | 58 | |||
Note: Where plantar pressure data provided mean (SD) kPa *(SE). All patients included in the above studies had diabetic peripheral neuropathy.
Studies monitored pressure across both feet.
This case‐study provided feedback continuously for 2 weeks to a single participant with an active foot ulcer. The ulcer size reduced from baseline to end of retention.
Although a reduction in plantar pressure existed at the end of retention, only 50% of steps were below the maximum pressure threshold (80% of baseline), instead of the recommended 70% of steps.
Plantar pressure at the first MTH significantly reduced 1 day after baseline, however at the end of retention there were no significant changes from receiving feedback.
This study randomised patients into 2 groups: feedback and no‐feedback. In addition, pressure at 1‐5 MTHs and heel were analysed.
This study randomised patients into two groups: intervention (receiving continuous pressure feedback) and control (no pressure feedback). Patients in the intervention group received feedback throughout daily‐life when sustained high pressure was detected. No pressure data was reported.